Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 36Terminated 10Active not recruiting 7Recruiting 5Unknown 3Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

NSCLC 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 117Bevacizumab 102Oxaliplatin 99Capecitabine 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 68Magnetic Resonance Spectroscopy 65Fluorouracil 63Injections 62sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 50fludarabine 47Standard of Care 46Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43Biopsy 43venetoclax 42Leucovorin 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Diphenhydramine × Clear all
NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
120 enrolled
Thoracic

NSCLC

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
430 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡